Verrica Pharmaceuticals Inc.
General ticker "VRCA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $54.9M (TTM average)
Verrica Pharmaceuticals Inc. does not follow the US Stock Market performance with the rate: -6.6%.
Estimated limits based on current volatility of 10.5%: low 6.97$, high 8.60$
Factors to consider:
- Total employees count: 71 (-29.0%) as of 2024
- Top business risk factors: Liquidity and credit risks, Limited operating history, Product returns exceeding reserves, Economic downturns and volatility, Third-party risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.80$, 16.78$]
- 2025-12-31 to 2026-12-31 estimated range: [2.47$, 9.73$]
Financial Metrics affecting the VRCA estimates:
- Negative: with PPE of -4.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -172.49 <= 0.33
- Positive: Inventory ratio change, % of -3.55 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VRCA quotes
Long-term VRCA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $9.03MM | $2.59MM | $7.48MM |
| Operating Expenses | $30.33MM | $68.35MM | $73.40MM |
| Operating Income | $-21.30MM | $-65.76MM | $-65.92MM |
| Non-Operating Income | $-3.19MM | $-1.24MM | $-10.66MM |
| Interest Expense | $2.17MM | $3.96MM | $9.41MM |
| R&D Expense | $12.20MM | $20.30MM | $11.84MM |
| Income(Loss) | $-24.49MM | $-67.00MM | $-76.58MM |
| Profit(Loss)* | $-24.49MM | $-67.00MM | $-76.58MM |
| Stockholders Equity | $40.03MM | $19.76MM | $-9.86MM |
| Inventory | $0.00MM | $1.02MM | $2.46MM |
| Assets | $44.72MM | $81.60MM | $54.13MM |
| Operating Cash Flow | $-18.65MM | $-38.58MM | $-60.93MM |
| Capital expenditure | $0.30MM | $0.36MM | $0.03MM |
| Investing Cash Flow | $54.04MM | $-0.36MM | $-0.02MM |
| Financing Cash Flow | $-16.87MM | $74.21MM | $37.73MM |
| Earnings Per Share** | $-7.17 | $-14.78 | $-14.78 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.